Skip to content
Search

Latest Stories

Submit Guest Post

US health regulator approves Cipla’s inhalation solution

Shilpa Sharma
By Shilpa SharmaJun 24, 2021
Shilpa Sharma
See Full Bio

PHARMACEUTICAL major Cipla received final consent from the US health regulator for Arformoterol Tartrate inhalation solution.

The approved product is used to treat conditions like chronic bronchitis and emphysema in the US market.

The company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the United States Food and Drug Administration (US FDA), Cipla said in a regulatory filing on Wednesday (23).

It is a generic version of Sunovion Pharmaceuticals Inc's Brovana.

Brovana is used in maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Brovana had sales of around $438 million (£314m) in the US for the 12-month period ending April 2021.

The new product is available for shipping immediately, Cipla said.

ciplaus
Add EasternEye As Your Trusted Source
preferred source on google news

Related News

Sanjay Bhandari's extradition appeal opens in London
Business

Sanjay Bhandari's extradition appeal opens in London

Rupert Murdoch looks on as he walks on the day of the hearing on the contentious matter of succession of Rupert Murdoch's global television and publishing empire, in Reno, Nevada, US, September 23, 2024. (Photo: Reuters)
Business

Murdoch's bid to secure eldest son's control of media empire fails

Kamlesh Pattni faces UK sanctions for illicit gold trade
Business

Kamlesh Pattni faces UK sanctions for illicit gold trade

Sanjay Malhotra speaks during the 67th Foundation Day of the Directorate of Revenue Intelligence (DRI) in New Delhi on December 4, 2024. (Photo: Getty Images)
Business

India appoints Sanjay Malhotra as new central bank governor

EasternEye

More For You

Restaurant

The UK restaurant market is growing, but the recovery is expected to favour larger and premium operators

iStock

UK's £18.7bn restaurant market has one big problem for independents

  • The UK restaurant market is forecast to reach £18.7 billion in 2026.
  • Fine dining is expected to lead growth, while independent restaurants continue to lose ground.
  • Rising costs and cautious consumer spending are likely to keep pressure on smaller operators.

The UK restaurant market is expected to grow to £18.7 billion in 2026, but the latest industry forecasts suggest the gains will not be shared equally across the sector.

According to Lumina Intelligence's UK Restaurant Market Report, overall market growth is expected despite ongoing pressure from higher operating costs, inflation and cautious consumer spending. While premium restaurants are forecast to perform well, many independent operators are expected to face another difficult year.

Keep ReadingShow less